Table 6.

Clinical trials on DEEs

1	Study Title: Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
	Recruiting: Not yet
	Has results: No
	Conditions: SCN8A DEE syndrome
	Interventions: Drug: NBI-921352, placebo
	Locations: Neurocrine Clinical Site, Washington, DC
2	Study Title: XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
	Recruiting: Yes
	Has results: No
	Conditions: Epilepsy, epilepsy in children, epilepsy; seizure disease, brain diseases, central nervous system diseases, nervous system diseases. epileptic syndromes
	Interventions: Drug: XEN496, placebo
	Locations: Children’s Hospital of Colorado, Aurora, CO; Northwest Florida Clinical Research Group, Gulf Breeze, FL; Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL; Columbia University Irving Medical Center, New York, NY; The Cleveland Clinic Foundation, Cleveland, OH; Oregon Health and Science University, Portland, OR; MultiCare Health System-Mary Bridge Pediatrics-Tacoma, Tacoma, WA; Sydney Children’s Hospital, Sydney, NSW, Australia; Children’s Health Queensland Hospital and Health Service, South Brisbane, QLD, Australia; Austin Health, Heidelberg, VIC, Australia
3	Study Title: An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
	Recruiting: Yes
	Has results: No
	Conditions: Epilepsy, epilepsy in children, seizure disease, brain diseases, central nervous system diseases, nervous system diseases, epileptic syndromes
	Interventions: Drug: XEN496, placebo
	Locations: MultiCare Health System-Mary Bridge Pediatrics-Tacoma, Tacoma, WA
4	Study Title: Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies
	Recruiting: No
	Has results: Yes
	Conditions: Developmental and/or epileptic encephalopathies
	Interventions: Drug: TAK-935, placebo
	Locations: Xenoscience, Phoenix, AZ; Medsol Clinical Research Center, Port Charlotte, FL; University of South Florida, Tampa, FL; Center for Integrative Rare Disease Research, Atlanta, GA; Bluegrass Epilepsy Research, Lexington, KY; Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD; The Comprehensive Epilepsy Care Center for Children and Adults, St. Louis, MO; Northeast Regional Epilepsy Group, Hackensack, NJ; Thomas Jefferson University, Philadelphia, PA; Medical University of South Carolina, Charleston, SC; University of Virginia Health Sciences Center, Charlottesville, VA
5	Study Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy In Pediatric Participants With Developmental and/or Epileptic Encephalopathies
	Recruiting: No
	Has results: Yes
	Conditions: Epilepsy, Dravet syndrome, Lennox–Gastaut syndrome
	Interventions: Drug: TAK-935, placebo
	Locations: Phoenix Children's Hospital, Phoenix, AZ; Children’s Hospital Los Angeles, Los Angeles, CA: Colorado Children’s Hospital, Aurora, CO. Nicklaus Children’s Hospital, Miami, FL; Pediatric Neurology PA, Orlando, FL; Rare Disease Research, LLC, Atlanta, GA; Center for Rare Neurological Diseases, Norcross, GA; Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, IL; Mayo Clinic-PPDS, Rochester, MN; Northeast Regional Epilepsy Group, Hackensack, NJ; Children’s Hospital at Saint Peter’s University Hospital, New Brunswick, NJ; Columbia University Medical Center, New York, NY; Wake Forest Baptist Medical Center, Winston-Salem, NC; Medical University of South Carolina, Charleston, SC; Cook Children’s Medical Center, Fort Worth, TX; Monash Children’s Hospital, Clayton, VIC, Australia; Austin Hospital, Heidelberg West, VIC, Australia; Hospital For Sick Children, Toronto, ON, Canada; Peking University First Hospital, Beijing, China; Capital Medical University (CMU)-Beijing Children's Hospital, Beijing, China; Beijing Children’s Hospital, Capital Medical University, Beijing, China. Xiangya Hospital Central South University, Changsha, China; Children’s Hospital of Fudan University, Shanghai, China; Shenzhen Children’s Hospital, Shenzhen, China; Sheba Medical Center-PPDS, Tel Hashomer, Ramat Gan, Israel; Soroka University Medical Centre, Bear Sheva, Israel; Bnai Zion Medical Center, Haifa, Israel; Edith Wolfson Medical Center, Holon, Israel; Hadassah Medical Center, Jerusalem, Israel; Schneider Childrens Medical Center of Israel, Petach Tikva, Israel; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Uniwersyteckie Centrum Kliniczne PPDS, Gdansk, Pomorskie, Poland; NZOZ Centrum Neurologii Dzieciecej i Leczenia Padaczki, Kielce, Swietokrzyskie, Poland; Szpital Kliniczny im. H. Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Wielkopolskie, Poland; Centrum Medyczne Plejady, Krakow, Poland; Samodzielny Publiczny Dzieciecy Szpital Kliniczny w Warszawie, Warsaw, Poland; Instytut Pomnik Centrum Zdrowia Dziecka, Warsaw, Poland; Centro Hospitalar Lisboa Central-Hospital Dona Estefania, Lisboa, Portugal; Centro Hospitalar Lisboa Norte, E.P.E. Hospital de Santa Maria, Lisboa, Portugal; Largo da Maternidade de Julio Dinis Centro Materno Infantil do Norte, Porto, Portugal; Clinica Universidad Navarra, Pamplona, Navarra, Spain; Hospital Vithas La Salud, Granada, Spain. Hospital Ruber Internacional, Madrid, Spain; Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain

Clinical trials gathered from ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home) interrogated on October 27, 2021 with the keyword “developmental and epileptic encephalopathy.”